Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Drug Profile

Research programme: DNA-based monoclonal antibody therapeutics - Inovio Pharmaceuticals

Alternative Names: BEAT-HIV programme

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Inovio Pharmaceuticals; MedImmune; Wistar Institute
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chikungunya virus infections; HIV infections; Influenza virus infections; Pneumonia; Prostate cancer

Most Recent Events

  • 21 Sep 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 21 Sep 2017 Preclinical trials in Pneumonia (Prevention) in USA (Parenteral)
  • 21 Sep 2017 Inovio Pharmaceuticals plans a phase I trial for Ebola virus infections in 2018 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top